trending Market Intelligence /marketintelligence/en/news-insights/trending/0zjoeoslmllricnqju7fhg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA approves Dexcom's glucose monitoring system

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


US FDA approves Dexcom's glucose monitoring system

The U.S. FDA approved DexCom Inc.'s G5 Mobile CGM system, a continuous glucose monitoring system, with a non-adjunctive designation.

In July, an FDA selected panel of experts deemed the system safe and effective, with its benefits outweighing the risks with the proposed indications for use. The FDA has followed the expert recommendation and made the system the first and only continuous glucose monitoring system in the U.S. to have a non-adjunctive designation.

The new non-adjunctive indication expands the use of the system as a replacement to finger stick glucose testing for diabetes treatment decisions. With the new label indication, the system only requires two finger pricks per day for calibration.